A meeting of the U.S. FDA's Antimicrobial Drugs Advisory Committee is scheduled for June 8, 2023, to discuss the biologics license application (BLA) for nirsevimab (Beyfortus®), a long-acting respiratory syncytial virus (RSV) F protein inhibitor, single dose monoclonal antibody (mAbs).
Will the FDA Approve the New RSV Monoclonal Antibody for Infants
A meeting of the U.S. FDA's Antimicrobial Drugs Advisory Committee is scheduled for June 8, 2023, to discuss the biologics license application (BLA) for nirsevimab (Beyfortus®), a long-acting respiratory syncytial virus (RSV) F protein inhibitor, single dose monoclonal antibody (mAbs).
Will U.S. FDA Approve New RSV Immunization for Infants
A meeting of the U.S. FDA's Antimicrobial Drugs Advisory Committee is scheduled for June 8, 2023, to discuss the biologics license application (BLA) for nirsevimab (Beyfortus®), a long-acting respiratory syncytial virus (RSV) F protein inhibitor, single dose monoclonal antibody (mAbs).
Will U.S. FDA Approve RSV Immunization for Infants
A meeting of the U.S. FDA's Antimicrobial Drugs Advisory Committee is scheduled for June 8, 2023, to discuss the biologics license application (BLA) for nirsevimab (Beyfortus®), a long-acting respiratory syncytial virus (RSV) F protein inhibitor, single dose monoclonal antibody (mAbs).
Japan's Mpox Outbreak Was Connected with International Travel
The Lancet recently published a Correspondence that concluded the continuous reporting of new mpox cases in Japan suggests that ongoing local transmission of the sexually transmitted virus might be occurring.
The first imported mpox case in Japan was reported on July 25, 2022, and patients have been sporadically reported since then, mainly with a history of international travel or after having been in contact with travelers.
In Japan, 8 mpox cases were reported in 2022.